Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.81 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | RHOC | P08134 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | THRB | P10828 | 1/20 | 0.81 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.81 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.81 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.78 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.78 |
| ▸ | PDE6D | O43924 | 4/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15475115 | 1.00 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL538509 | 1.00 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12520033 | 1.00 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL518254 | 0.95 | HMGCR (0.73) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13450913 | 0.95 | HMGCR (0.72) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL21637553 | 0.94 | PDE6D (0.76) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL8931058 | 0.94 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL469704 | 0.92 | HMGCR (0.68) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL9976581 | 0.92 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5240504 | 0.92 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2413911-B1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA D D NOVO MESTO (SI) | 2014-02-19 | — | — | EP | claimed |
| EP-2413911-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., Novo Mesto (SI) | 2012-02-08 | — | — | EP | claimed |
| WO-2010112222-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., NOVO MESTO (SI) | 2010-10-07 | — | — | WO | claimed |
| US-20090099371-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT | JUBILANT ORGANOSYS LTD. (IN) | 2009-04-16 | — | — | US | claimed |
| EP-1979313-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT | Jubilant Organosys Limited (IN) | 2008-10-15 | — | — | EP | claimed |
| WO-2007088553-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT | JUBILANT ORGANOSYS LIMITED (IN) | 2007-08-09 | — | — | WO | claimed |
| WO-2017060885-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2017-04-13 | — | — | WO | disclosed |
| EP-2413911-B1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA D D NOVO MESTO (SI) | 2014-02-19 | — | — | EP | disclosed |
| EP-2240442-B1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO LTD (KR) | 2012-06-20 | — | — | EP | disclosed |
| US-8124790-B2 | Preparation process useful in synthesis of atorvastatin | MEDICHEM KOREA CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| EP-2413911-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., Novo Mesto (SI) | 2012-02-08 | — | — | EP | disclosed |
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO., LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| WO-2010112222-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., NOVO MESTO (SI) | 2010-10-07 | — | — | WO | disclosed |
| WO-2009084773-A2 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA. CO., LTD. (KR) | 2009-07-09 | — | — | WO | disclosed |
| EP-2075246-A1 | A process for preparation of amorphous form of atorvastatin hemi-calcium salt | M. J. Institute of Research (IN) | 2009-07-01 | — | — | EP | disclosed |
| US-20090099371-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT | JUBILANT ORGANOSYS LTD. (IN) | 2009-04-16 | — | — | US | disclosed |
| EP-1979313-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT | Jubilant Organosys Limited (IN) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088553-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT | JUBILANT ORGANOSYS LIMITED (IN) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006048888-A1 | NOVEL PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT | JUBILANT ORGANOSYS LIMITED (IN) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099371-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT | HMGCR, ACSS2, NPC1L1 | HMGCR 1/4885SLCO1B1 152/4885ABCB11 678/4885 |
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | HMGCR, DHCR7, LIPA | HMGCR 1/4885SLCO1B1 776/4885ABCB11 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.